Latest AVMA Podcast Features Fourth Of July Pet Safety Tips The sensory extravaganza of Fourth of July fireworks can be a nightmare of loud, unpredictable sounds and flashes of light for our pets, who are best left safe at home with plenty of water, soothing background noise and, if necessary, appropriate anxiety medication prescribed by a veterinarian. This is the advice given by Dr.
Source: www.medicalnewstoday.comWhite Blood Cells Could Tell Your Fortune BIN those tarot cards and cancel the visit to the palm reader. It might one day be possible to predict how long you'll live from a sample of your white blood cells. It is well known that the children of long-lived parents tend to be long-lived too, but no one knows why. As white blood cells fend off infection, in effect they are delaying death.
Source: www.medicalnewstoday.comPenile Rehabilitation In The Radical Prostatectomy Patient ORLANDO, FL (UroToday.com) - Dr. Ira Sharlip moderated a debate on penile rehabilitation. A consequence of radical prostatectomy (RP) is ED and its prevalence is reported between 9-93%. How penile rehabilitation is given and whether it works is debated. The purpose of penile rehabilitation is to provide oxygen to the corpora cavernosa for both prevention and recovery in post-RP patients. Dr.
Source: www.medicalnewstoday.comFurther Steps In Generation Change At Boehringer Ingelheim Dr Alessandro Banchi (62), Chairman of the Board of Managing Directors at Boehringer Ingelheim GmbH and responsible for Marketing and Sales, has decided after more than 35 years with the Corporation to retire at the end of 2008. His successor will be the Vice-Chairman of the Board of Managing Directors, Dr Andreas Barner (55), who is currently responsible for Research, Development and
Medicine.
Source: www.medicalnewstoday.comThallion Receives Health Canada Approval To Initiate Phase II Study For TLN-232 In Metastatic Melanoma Patients Thallion Pharmaceuticals Inc. (TSX:TLN) announced it has received authorization from the Therapeutic Products Directorate of
Health Canada to initiate a Phase II clinical trial evaluating TLN-232 as a treatment for metastatic melanoma in patients that have failed at least one prior therapy. The TLN-232 trial is the second Phase II study to be initiated this year from Thallion's oncology pipeline.
Source: www.medicalnewstoday.comOn National HIV Testing Day Chembio Reports Completion Of Pediatric Study Needed For Expanded Product Usage Chembio Diagnostics, Inc. (OTCBB: CEMI) ("Chembio" or the "Company") reported recently, National HIV Testing Day, that it has completed a clinical study designed to evaluate the performance of its two FDA (United States Food & Drug Administration) approved rapid HIV tests on a pediatric subpopulation (ages 13-17 years of age).
Source: www.medicalnewstoday.com
# posted by Network @ 4:00 PM
